DRTG(SH:600329) Ge Long Hui A P P·2025-08-14 08:22Core Insights - The company reported a revenue of 2.651 billion yuan for the first half of 2025, reflecting a year-on-year decline due to the exclusion of revenue from its wholly-owned subsidiary Tianjin Zhongxin Pharmaceutical Co., Ltd. after its equity was transferred at the end of 2024 [1] - The main industrial revenue was 2.645 billion yuan, showing a year-on-year growth of 0.87% [1] - The net profit attributable to shareholders reached 1.928 billion yuan, a significant increase of 193.08%, primarily driven by a tax-adjusted net gain of 1.308 billion yuan from the transfer of a 12% stake in Tianjin Shike Pharmaceutical Co., Ltd. [1] - The net profit attributable to shareholders after excluding non-recurring gains and losses was 596 million yuan, a decrease of 5.93%, mainly due to the absence of investment income from the previously held 25% stake in Tianjin Shike [1] - After excluding the impact of the investment income from the joint venture, the net profit attributable to the parent company increased by 12.86% year-on-year [1]